RecruitingNCT05483374

The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers

The Observational Clinical Registry of the European Reference Network on Rare Adult Solid Cancers: the Protocol for the Rare Head and Neck Cancers


Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Enrollment

13,600 participants

Start Date

May 31, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Cancer care for head and neck cancers is multidisciplinary and complex and knowledge on the rare ones is limited. There is a wide consensus that to support clinical research on rare cancers, clinical registries should be developed within networks specializing in rare cancers. Our hypothesis is that our head and neck cancer registry established in the framework of the European reference network on rare adults solid cancers will help to: describe the natural history of rare head and neck cancers; evaluate factors that influence prognosis; assess treatment effectiveness; measure indicators of quality of care. The registry is a prospective observational real-world registry. It collects data from already available registries/database and/or directly from expert health care providers (HCP). Information are prospectively collected on patient characteristics; exposure, outcomes and potential confounders (https://euracan.eu/research/starter/rare-head-and-neck-cancer-registry/#codebook). The registry if federated (i.e. data are stored by the data provider). Analyses will be performed using the federated learning approach which split computations into a local part and a central part. The data providers will share sub-computations only. Data quality checks are envisioned to assess whether data value are present, valid and believable. Validity and plausibility checks are embedded in the electronic case report form (CRF) in the form of alerts and errors during the data input. Additional checks are implemented in R and run using the federated learning to ensure a central data quality monitoring. The data analyses will include descriptive statistics showing frequency and patterns of patients' and cancers' variables; analytical analyses investigating the association of patients/disease and/or treatment characteristics and health outcomes. Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is the coordinator of the EURACAN registry as well as a data provider. At the INT, and at each HCP involved, responsible investigators ensure that the EURACAN registry will be implemented in compliance with the protocol, following the instructions and procedures described herein. Each HCP is a controller and will identify a data processor. The processing of patients' personal data taking part in the registry is compliant with local privacy legislation and the General Data Protection Regulation 2016/679 of the EU.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear (i.e. squamous carcinoma; adenocarcinoma; neuroendocrine; adenosquamous carcinoma, teratocarcinosarcoma, NUT carcinoma, odontogenic tumors) + neuroendocrine and adenocarcinoma in hypopharynx; oropharynx; larynx; oral cavity and lip + odontogenic carcinoma in oral cavity.
  • Adult patients (aged ≥18 years).
  • Diagnosis performed or verified by the expert centre entering the patient information in the registry.
  • Patients entering the HCP at any clinical phase of the disease (diagnosis, treatment of primary cancer, treatment of recurrence, treatment of M+ etc.). The HCP can decide, based on its resources, the number of patients on whom it can collect data.
  • New patients managed by the HCP from 2021 onwards plus patients managed by the HCP, who are actively followed up at the hospital, with year of diagnosis dating back to maximum 2018.

Exclusion Criteria1

  • • Patients (aged \< 18 years)

Interventions

OTHERobservation

Not applicable, it is an observational registry


Locations(12)

Masaryk Memorial Cancer Institute

Brno, Brno, Czechia

Assistance Publique-Hôpitaux de Paris - Hôpital Tenon

Paris, Paris, France

University Hospital Essen

Essen, Hesse, Germany

IRCCS Ospedale Policlinico San Martino

Genova, Genova, Italy

IRCCS Ospedale San Raffaele

Milan, Milano, Italy

IRCCS Istituto Europeo di Oncologia

Milan, Milano, Italy

IRCCS Istituto Clinica Humanitas

Rozzano, Milano, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Milan, Italy

Centro Nazionale di Adroterapia Oncologica

Pavia, Pavia, Italy

Nuovo Ospedale di Prato - S. Stefano

Prato, Prato, Italy

IRCCS Istituto Nazionale Tumori Regina Elena

Roma, Roma, Italy

Fundacion Profesor Novoa Santos

A Coruña, A Coruña, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05483374


Related Trials